2022
Emerging Trends in the Pathological Research of Human Papillomavirus-positive Oropharyngeal Squamous Cell Carcinoma
Crane J, Shi Q, Xi Y, Lai J, Pham K, Wang H. Emerging Trends in the Pathological Research of Human Papillomavirus-positive Oropharyngeal Squamous Cell Carcinoma. Journal Of Clinical And Translational Pathology 2022, 2: 31-36. PMID: 36275841, PMCID: PMC9585478, DOI: 10.14218/jctp.2022.00004.Peer-Reviewed Original ResearchOropharyngeal squamous cell carcinomaSquamous cell carcinomaCell carcinomaHuman papillomavirusHuman papillomavirus-positive oropharyngeal squamous cell carcinomaHPV-positive oropharyngeal squamous cell carcinomaHPV-negative oropharyngeal squamous cell carcinomaActive human papillomavirusNew targetsLong-term survivalPotential new targetsDefinitive treatmentHPV 16Treatment optionsSurvival prognosisTumor prognosisAdvanced stageHealth responsePrecision treatmentPrecision medicinePatientsCarcinomaPrognosisTreatmentPathological research
2021
Potential role of IFN-α in COVID-19 patients and its underlying treatment options
Yang L, Wang J, Hui P, Yarovinsky TO, Badeti S, Pham K, Liu C. Potential role of IFN-α in COVID-19 patients and its underlying treatment options. Applied Microbiology And Biotechnology 2021, 105: 4005-4015. PMID: 33950278, PMCID: PMC8096625, DOI: 10.1007/s00253-021-11319-6.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSARS-CoV-2 infectionIFN-α subtypesRespiratory virus diseasesCOVID-19 patientsImmunoregulatory effectsInflammatory responseSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2COVID-19 pathogenesisTreatment of patientsUncontrolled inflammatory responseSyndrome coronavirus 2Interferon-stimulated gene expressionPotential therapeutic strategySeverity of infectionSARS-CoV-2Virus diseaseInnate immune systemPossible side effectsCOVID-19 diseaseViral infection treatmentDrug candidatesCoronavirus 2Treatment options
2017
A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma
Wu Q, Pi L, Le Trinh T, Zuo C, Xia M, Jiao Y, Hou Z, Jo S, Puszyk W, Pham K, Nelson DR, Robertson K, Ostrov D, Rameshwar P, Xia CQ, Liu C. A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma. Molecular Therapy 2017, 25: 2299-2308. PMID: 28865999, PMCID: PMC5628867, DOI: 10.1016/j.ymthe.2017.08.005.Peer-Reviewed Original ResearchConceptsC57/B6 miceHepatocellular carcinomaGlypican-3B6 miceIntravenous infusionImmune responseTumor-specific cytotoxic T lymphocyte responsesCytotoxic T lymphocyte responsesBALB/c miceTumor necrosis factor alphaFirst preclinical evidenceLocal immune responseT lymphocyte responsesLimited treatment optionsDurable tumor regressionNecrosis factor alphaAnti-HCC effectsCultured HCC cellsCTL responsesLymphocyte responsesPreclinical evidenceAntibody therapyMost HCC tissuesHigh morbidityTreatment options